Keith M Sullivan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3056055/publications.pdf

Version: 2024-02-01

66 papers	3,007 citations	236925 25 h-index	161849 54 g-index
67 all docs	67 docs citations	67 times ranked	3160 citing authors

#	Article	IF	Citations
1	Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. Rheumatology, 2022, 61, 4155-4162.	1.9	8
2	EPR22-118: Incidence of Herpes Zoster in Immunocompromised Individuals and Zoster Vaccination as an Effective Preventative Strategy. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, EPR22-118.	4.9	0
3	Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 137-143.	2.4	15
4	Largeâ€Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis. Arthritis and Rheumatology, 2021, 73, 660-670.	5.6	10
5	Quantifying Skin Stiffness in Graft-Versus-Host Disease, Morphea, and Systemic Sclerosis Using Acoustic Radiation Force Impulse Imaging and Shear Wave Elastography. Journal of Investigative Dermatology, 2021, 141, 924-927.e2.	0.7	10
6	Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. Human Vaccines and Immunotherapeutics, 2021, 17, 4144-4154.	3.3	16
7	Clinical and Molecular Findings after Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. Arthritis Care and Research, 2021, , .	3.4	3
8	Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, , .	2.4	2
9	Safety and efficacy of HSCT for systemic sclerosis across clinical trials. Nature Reviews Rheumatology, 2020, 16, 661-661.	8.0	4
10	Machine learning predicts stem cell transplant response in severe scleroderma. Annals of the Rheumatic Diseases, 2020, 79, 1608-1615.	0.9	29
11	Cross-trial comparisons in reviews: proceed with caution. Nature Reviews Rheumatology, 2020, 16, 663-664.	8.0	4
12	Clinical and Neuroimaging Correlates of Post-Transplant Delirium. Biology of Blood and Marrow Transplantation, 2020, 26, 2323-2328.	2.0	0
13	7. Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?. Open Forum Infectious Diseases, 2020, 7, S3-S4.	0.9	0
14	Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). Biology of Blood and Marrow Transplantation, 2019, 25, 2474-2481.	2.0	30
15	Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation. JAMA - Journal of the American Medical Association, 2019, 322, 123.	7.4	143
16	Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. Annals of the Rheumatic Diseases, 2019, 78, 1371-1378.	0.9	43
17	Allogeneic HSCT for autoimmune disease: a shared decision. Nature Reviews Rheumatology, 2019, 15, 701-702.	8.0	6
18	How I treat refractory chronic graft-versus-host disease. Blood, 2019, 133, 1191-1200.	1.4	70

#	Article	IF	Citations
19	Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease. JAMA Dermatology, 2019, 155, 833.	4.1	6
20	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 845-854.	2.0	69
21	Application of stem cell transplantation in autoimmune diseases. Current Opinion in Hematology, 2019, 26, 392-398.	2.5	12
22	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Annals of the Rheumatic Diseases, 2019, 78, 122-130.	0.9	141
23	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. American Journal of Hematology, 2019, 94, 446-454.	4.1	56
24	Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality. Blood, 2019, 134, 5731-5731.	1.4	0
25	A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503. Blood, 2019, 134, 4592-4592.	1.4	0
26	Shared Decision-Making in Hematopoietic Stem Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 883-884.	2.0	9
27	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. New England Journal of Medicine, 2018, 378, 35-47.	27.0	417
28	Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease. Archives of Pathology and Laboratory Medicine, 2018, 142, 1098-1105.	2.5	6
29	Autologous Stem-Cell Transplantation for Severe Scleroderma. New England Journal of Medicine, 2018, 378, 1066-1067.	27.0	17
30	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1928-1935.	2.0	2
31	Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1961-1964.	2.0	47
32	An mHealth Pain Coping Skills Training Intervention for Hematopoietic Stem Cell Transplantation Patients: Development and Pilot Randomized Controlled Trial. JMIR MHealth and UHealth, 2018, 6, e66.	3.7	31
33	Efficacy and safety of highâ€dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. Hematological Oncology, 2017, 35, 752-759.	1.7	5
34	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica, 2017, 102, 1823-1832.	3.5	43
35	Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases. Biology of Blood and Marrow Transplantation, 2017, 23, 1463-1472.	2.0	8
36	Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 207-211.	2.0	97

#	Article	IF	Citations
37	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. Journal of Hematology and Oncology, 2016, 9, 71.	17.0	20
38	Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. Clinical Infectious Diseases, 2016, 63, 999-1006.	5.8	63
39	Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement. Arthritis and Rheumatology, 2016, 68, 2361-2371.	5.6	27
40	Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2014, 20, 257-263.	2.0	15
41	A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood, 2014, 124, 2921-2929.	1.4	145
42	Gastric Antral Vascular Ectasia and Its Clinical Correlates in Patients with Early Diffuse Systemic Sclerosis in the SCOT Trial. Journal of Rheumatology, 2013, 40, 455-460.	2.0	67
43	Haemopoietic stem-cell transplantation for systemic sclerosis. Lancet, The, 2012, 379, 219.	13.7	6
44	Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2012, 18, 1471-1478.	2.0	62
45	Acute Kidney Injury in Patients with Systemic Sclerosis Participating in Hematopoietic Cell Transplantation Trials in the United States. Biology of Blood and Marrow Transplantation, 2011, 17, 674-681.	2.0	21
46	Renal Shielding and Dosimetry for Patients With Severe Systemic Sclerosis Receiving Immunoablation With Total Body Irradiation in the Scleroderma: Cyclophosphamide or Transplantation Trial. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1248-1255.	0.8	27
47	High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation. Blood, 2011, 118, 2012-2012.	1.4	1
48	Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 4127-4127.	1.4	9
49	The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 4065-4065.	1.4	0
50	Hematopoietic Cell Transplantation for Autoimmune Disease: Updates from Europe and the United States. Biology of Blood and Marrow Transplantation, 2010, 16, S48-S56.	2.0	77
51	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. Blood, 2010, 116, 3523-3523.	1.4	0
52	Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies. Blood, 2010, 116, 3541-3541.	1.4	0
53	Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?. Biology of Blood and Marrow Transplantation, 2009, 15, 447-453.	2.0	27
54	Total Body Irradiation 1350cGy/Fludarabine (TBI/FLU) vs Myeloablative Busulfan/Fludarabine (Bu/Flu) Preparation in Adult Recipients of Dual Umbilical Cord Blood (UCB) Transplantation: Superior Engraftment with Low Treatment-Related Mortality. Blood, 2008, 112, 4403-4403.	1.4	0

#	Article	IF	Citations
55	Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.. Blood, 2008, 112, 3325-3325.	1.4	0
56	Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.. Blood, 2008, 112, 2180-2180.	1.4	0
57	High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood, 2007, 110, 1388-1396.	1.4	240
58	Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients.. Blood, 2007, 110, 2007-2007.	1.4	1
59	Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival.. Blood, 2006, 108, 5399-5399.	1.4	1
60	Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.. Blood, 2005, 106, 2896-2896.	1.4	5
61	Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune) Tj ETQq1 1 0.784314 rgBT /Overlock	3.2	56
62	Hematopoietic Cell Transplantation for Sickle Cell Disease: Updated Results of the Multicenter Trial.. Blood, 2004, 104, 104-104.	1.4	7
63	High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood, 2002, 100, 1602-1610.	1.4	161
64	Bone marrow transplantation for non-malignant disease. International Journal of Hematology, 2002, 76, 169-170.	1.6	4
65	High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood, 2002, 100, 1602-10.	1.4	61
66	Bone Marrow Transplantation for Sickle Cell Disease. New England Journal of Medicine, 1996, 335, 369-376.	27.0	545